Johnson & Johnson (JNJ) Position Reduced by Peoples Financial Services CORP.

Peoples Financial Services CORP. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,018 shares of the company’s stock after selling 1,650 shares during the period. Johnson & Johnson makes up 2.1% of Peoples Financial Services CORP.’s portfolio, making the stock its 9th largest holding. Peoples Financial Services CORP.’s holdings in Johnson & Johnson were worth $3,744,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares in the last quarter. Selective Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $105,000. Ifrah Financial Services Inc. acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $203,000. Exane Asset Management acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $206,000. Finally, Peak Capital Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $207,000. Institutional investors own 67.32% of the company’s stock.

Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target for the company in a research report on Wednesday, March 27th. BMO Capital Markets increased their price objective on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday. Raymond James increased their price objective on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $146.40.

Shares of Johnson & Johnson stock traded down $1.00 during trading on Friday, hitting $137.52. 10,485,289 shares of the stock traded hands, compared to its average volume of 6,120,494. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The firm has a market cap of $368.95 billion, a price-to-earnings ratio of 16.81, a P/E/G ratio of 2.38 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The company’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the business posted $2.06 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Position Reduced by Peoples Financial Services CORP.” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/johnson-johnson-jnj-stake-lowered-by-peoples-financial-services-corp.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Marijuana Stocks Future Looks Bright

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.